Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial

Lignende værker

• Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis
  af: Thomas Hueso, et al.
  Udgivet: (2025-04-01)
• PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
  af: Assia Taleb, et al.
  Udgivet: (2023-08-01)
• Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib
  af: Jack Fitzsimons, et al.
  Udgivet: (2024-06-01)
• Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial
  af: Wenjie Xiong, et al.
  Udgivet: (2024-01-01)
• Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
  af: Xiaowei Xu, et al.
  Udgivet: (2013-12-01)